Orion Portfolio Solutions LLC Cuts Position in Illumina, Inc. (NASDAQ:ILMN)

Orion Portfolio Solutions LLC decreased its position in Illumina, Inc. (NASDAQ:ILMNFree Report) by 74.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,172 shares of the life sciences company’s stock after selling 21,015 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Illumina were worth $959,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in ILMN. Quantbot Technologies LP acquired a new position in shares of Illumina during the 3rd quarter worth about $379,000. Kestra Private Wealth Services LLC boosted its holdings in Illumina by 15.3% in the third quarter. Kestra Private Wealth Services LLC now owns 4,684 shares of the life sciences company’s stock valued at $643,000 after purchasing an additional 621 shares in the last quarter. Sepio Capital LP increased its stake in Illumina by 19.5% in the third quarter. Sepio Capital LP now owns 10,102 shares of the life sciences company’s stock valued at $1,387,000 after purchasing an additional 1,651 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Illumina by 0.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 883,900 shares of the life sciences company’s stock worth $121,342,000 after purchasing an additional 6,970 shares in the last quarter. Finally, Van ECK Associates Corp lifted its position in shares of Illumina by 25.9% during the 3rd quarter. Van ECK Associates Corp now owns 141,567 shares of the life sciences company’s stock worth $19,434,000 after buying an additional 29,123 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Barclays boosted their target price on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Scotiabank decreased their target price on Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a research report on Monday, May 6th. Jefferies Financial Group started coverage on Illumina in a research note on Monday. They set a “hold” rating and a $115.00 price target on the stock. Finally, Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and an average price target of $162.29.

View Our Latest Stock Report on ILMN

Illumina Price Performance

Shares of NASDAQ ILMN opened at $103.37 on Tuesday. The company’s fifty day moving average is $119.00 and its two-hundred day moving average is $127.00. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. The firm has a market capitalization of $16.47 billion, a P/E ratio of -12.68 and a beta of 1.20. Illumina, Inc. has a one year low of $89.00 and a one year high of $213.12.

Illumina (NASDAQ:ILMNGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the previous year, the firm earned $0.08 earnings per share. The firm’s revenue was down 1.0% on a year-over-year basis. Analysts forecast that Illumina, Inc. will post 0.87 EPS for the current fiscal year.

Illumina Company Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Further Reading

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.